71
Participants
Start Date
July 31, 2012
Primary Completion Date
April 30, 2020
Study Completion Date
April 30, 2020
Brentuximab Vedotin
Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
Bendamustine
Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
Neulasta
(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
Center for Lymphoid Malignancies at CUMC, New York
British Columbia Cancer Agency, Vancouver
Princess Margaret Hospital, Toronto
Columbia University
OTHER